Your browser is no longer supported. Please, upgrade your browser.
ETNB 89bio, Inc. weekly Stock Chart
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-4.96 Insider Own- Shs Outstand13.79M Perf Week20.39%
Market Cap388.61M Forward P/E- EPS next Y-3.95 Insider Trans- Shs Float13.72M Perf Month11.34%
Income-63.50M PEG- EPS next Q-0.92 Inst Own- Short Float4.13% Perf Quarter14.57%
Sales- P/S- EPS this Y-210.60% Inst Trans1.80% Short Ratio8.97 Perf Half Y9.96%
Book/sh5.79 P/B4.77 EPS next Y-4.50% ROA- Target Price44.25 Perf Year-
Cash/sh6.07 P/C4.55 EPS next 5Y13.00% ROE- 52W Range14.00 - 47.25 Perf YTD4.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.59% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low97.14% ATR2.76
Employees22 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)58.89 Volatility18.43% 10.90%
OptionableNo Debt/Eq0.00 EPS Q/Q-107.80% Profit Margin- Rel Volume1.28 Prev Close28.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume63.23K Price27.60
Recom1.70 SMA2016.24% SMA5010.74% SMA2002.25% Volume80,777 Change-2.02%
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is BIO89-100, an engineered glycoPEGylated analog of fibroblast growth factor 21 that is in proof of concept Phase 1b/2a clinical trial in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver diseases with a high risk of NASH. It also focuses on the development and commercialization of other therapies related to NASH, and other liver and cardio-metabolic diseases. The company was founded in 2018 and is headquartered in San Francisco, California.